Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

Has the Enemy "MET" Its Match? Subgroup Analysis Results from VISION Study

Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents. See related...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical cancer research 2022-03, Vol.28 (6), p.1055-1057
Hauptverfasser: Rosner, Samuel, Spira, Alexander I
Format: Artikel
Sprache:eng
Schlagworte:
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Exons
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Mutation
Proto-Oncogene Proteins c-met - genetics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Emerging therapies have recently received approval for the treatment of MET exon 14 skipping non-small cell lung cancer (NSCLC). Further characterization of these therapies, such as tepotinib, is needed to identify patient subgroups most likely to derive benefit from these novel agents. See related article by Le et al., p. 1117.
ISSN:1078-0432
1557-3265
DOI:10.1158/1078-0432.CCR-21-4109